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Abstract | Genomic studies have greatly advanced our understanding of the multifactorial 
aetiology of type 2 diabetes mellitus (T2DM) as well as the multiple monogenic diabetes 
subtypes. In this Review, we discuss the existing pharmacogenetic evidence in both 
monogenic diabetes and T2DM, highlight the mechanistic insights from the study of side 
effects to antidiabetic drugs as well as their efficacy. The identification of extreme 
sulfonylurea sensitivity in patients with diabetes mellitus caused by heterozygous mutations 
in HNF1A represents a clear example of how pharmacogenetics can impact on patient care. 
However pharmacogenomic studies of response to antidiabetic drugs in T2DM has yet to 
translate into clinical practice, although some moderate genetic effects have now been 
described that merit follow up in genotype selected trials. We also discuss how future 
pharmacogenomic findings could provide insights into treatment response in diabetes that, 
complementary to other areas of human genetics, facilitates drug discovery and drug 
development for T2DM. 
Introduction 
In the past decade, genome-wide association studies (GWAS) and high-throughput 
sequencing, propelled by the fast development in affordable genomic technologies, have 
greatly advanced our understanding of the genetic aetiology of many common diseases1. 
Pharmacogenomic studies applying these genome-wide approaches to investigate drug 
response have also yielded important results2, 3. In this Review, and in this context, we 
discuss the genomic evidence that has strengthened our understanding of the multifactorial 
aetiology of type 2 diabetes mellitus (T2DM) and discuss the emerging evidence that a 
complex genetic architecture might underline the variation in response to antidiabetic drugs. 
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Genetic evidence in disease genomics is increasingly being used for target validation in drug 
discovery. We anticipate how robust pharmacogenomic evidence could provide more 
valuable information to predict both on-target and off-target effects in drug discovery and 
development.  
The multifactorial aetiology of T2DM  
T2DM is a complex metabolic disease characterized by hyperglycaemia resulting from 
functional impairment in insulin secretion, insulin action or both4. Both insulin resistance and 
secretory deficiency arise through the interplay of genetic and environmental risk factors5. 
GWAS, which have interrogated all the common genetic variants (minor allele frequency 
greater than 5%), have identified >120 T2DM risk loci6, 7. High-throughput sequencing 
studies, which could theoretically examine all the variants in the genome or at least the 
section that encodes proteins, have also enabled the discovery of rare variants (minor allele 
frequency <5%) at GWAS identified loci and novel loci for T2DM8, 9. Together these common 
variants with small to moderate effects and rare variants with relatively large impacts could 
account for ~15% of the total risk of developing T2DM and confirm its nature as a 
multisystem disorder6, 10. 
Glycaemic control is a key focus in the management of T2DM, and is associated with both 
microvascular and macrovascular benefits11-13. The treatment of T2DM has evolved with our 
understanding of the pathophysiology of this complex disease5. A wide range of drug 
treatment, characterized by different mechanism of action, is available to achieve glycaemic 
control in patients with T2DM (Figure 1)14. Apart from insulin replacement, traditional oral 
agents include the secretagogues that stimulate the pancreas to release insulin and the 
sensitizers that enhance the efficacy of insulin action14. New agents include the 
dipeptidylpeptidase-4 (DPP4) inhibitors, also known as the gliptins, that enhance the so-
called ‘incretin effect’ and promote glucose-stimulated insulin secretion15; as well as the 
sodium-glucose cotransporter-2 (SGLT-2) inhibitors that reduce hyperglycaemia by 
increasing glucose elimination via the urine16. Although these drugs are all effective at 
lowering glucose in patients with T2DM, glycaemic control often fails even after a 
combination of the available treatment options due to the progressive nature of the disease. 
Diabetes drug response can be considered at many levels, as outlined in Table 1, including 
the physiological response to the drug, or the long term effect of the drug in terms of 
microvascular or macrovascular risk reduction. In this Review, when considering drug 
response, we focus primarily on the glycaemic effect of drugs as this outcome has been the 
most studied. 
Monogenic diabetes mellitus 
With the increasing awareness that T2DM is highly heterogeneous, and as we understand 
more about the aetiology of the disease, we can begin to subdivide ‘T2DM’ into distinct 
aetiological subtypes. This development can be seen with the increasing identification of 
monogenic forms of the disease, which until the past 10-15 years were misclassified as type 
1 diabetes mellitus or T2DM. Understanding these aetiological subtypes has resulted in 
some of the earliest studies that provided the most clinically robust examples of 
pharmacogenetics to date. For example, patients with Maturity Onset Diabetes of the Young 
owing to mutations in HNF1A (which accounts for ~3% of all diabetes mellitus cases 
diagnosed under the age of 30 years) are extremely sensitive to sulfonylurea treatment, and 
can successfully transition off insulin treatment17. Similarly patients with neonatal diabetes 
due to KCNJ11 or ABCC8 mutations who have insulin dependent diabetes mellitus from 
soon after birth have been shown to respond to high dose sulfonylureas and to be able to 
transition off insulin onto oral sulfonylurea treatment18. These examples highlight how 
increasing awareness of aetiological subtypes of diabetes will enable a precise approach to 
treatment of diabetes mellitus and is an area of great interest. However, for the remainder of 
this review, we will focus on polygenic influences on drug response in T2DM.  
Pharmacogenomics and genetic architecture  
Pharmacogenetics aims to seek the genetic explanation of why individuals respond 
differently to drugs, both in terms of therapeutic efficacy as well as adverse drug reactions 
(ADR)19. Prior to the emergence of genome wide genotyping arrays, pharmacogenetic 
studies focused on candidate genes with known links to drug distribution, metabolism or 
response pathways19. With the development of cost-effective genomic technologies, 
genome-wide genotyping and sequencing has transformed this traditional pharmacogenetic 
approach into a more global pharmacogenomic approach that can systematically interrogate 
millions of genetic polymorphisms across the genome20, 21. Most published genome-wide 
studies of drug response are GWAS, and only a few such studies reported sequencing-
based investigations. One example of a sequencing-based study is the use of publicly 
available whole-genome sequence data on 482 samples to profile 231 pharmacogenetic 
genes22. In the same study, the authors also performed whole genome sequencing on 7 
family members to try to explain the genetic basis of their variable response to 
anticoagulation treatment. The two terms pharmacogenetics and pharmacogenomics are 
often used interchangeably, but in this Review we use pharmacogenomics to refer to studies 
using genome-wide approaches. 
Biomarker discovery for precision medicine remains the long-term goal of pharmacogenomic 
studies. However, an often under-appreciated benefit of such studies is that they can 
advance our understanding of the biological mechanism of drug action in humans by 
identifying variants in genes not previously thought to be associated with drug response. 
These genes might never have been included in traditional candidate gene approaches3.  
A fundamental issue underlying the validity and feasibility of pharmacogenomic studies is the 
genetic architecture of drug response23. In this context ‘genetic architecture’ refers to the 
number of response variants; the frequency spectrum of these response variants; the effect 
size spectrum of the variants; the physical distribution of the variants in the genome; and the 
amount of variation in drug response explained by these genetic variants (known as 
heritability). Whilst heritability determines the validity of pharmacogenomic studies, the other 
aspects of genetic architecture dictate the feasibility and design of pharmacogenomic 
studies. 
Adopting traditional twin and family study designs to estimate the heritability of drug 
treatment outcomes has been largely impractical, because family members may not develop 
the same disease or be treated with same drug. With the availability of GWAS data, new 
‘chip-based’ approaches have been developed to estimate heritability from population-based 
samples24. However, data from at least a few thousand individuals are required to achieve 
an accurate estimate of heritability by these methods25. Such methods, therefore, can be 
applied to estimate the heritability of treatment efficacy for commonly used drugs, but not the 
less frequent ADRs. 
In a study of GWAS data from 2,085 patients with T2DM, heritability of glycaemic response 
to metformin was estimated to be up to 34% (p=0.02)23. Furthermore, this investigation also 
found that the heritability is likely to be the result of many common response variants with 
small to moderate effect sizes scattered across the genome23. These results suggest that 
the genetic architecture of metformin efficacy is similar to that of T2DM and other complex 
traits. This similarity between the genetic architectures of T2DM and the treatment efficacy of 
metformin is likely to be rooted in the multifactorial aetiology of the disease. Variants in 
different genes or pathways might affect metformin treatment efficacy in patients whose 
pathophysiology is heterogeneous (for example, those individuals who are predominantly 
insulin resistant or those whose insulin secretion is deficient). Similar to metformin, other 
antidiabetic agents are also used to treat a combination of patients with heterogeneous 
pathophysiology. Therefore we anticipate that the genetic architecture of treatment efficacy 
for other antidiabetic agents to be similar to that of metformin response.  
To appreciate the scale of the heritability estimate of 34% for glycaemic response to 
metformin, it is necessary to put it into the context of other complex traits. In a 2015 study 
again using a population-based method, the heritability estimate for BMI was 
27%(S.E.=2.5%) 26, which is considerably lower than the heritability estimates of 40%~60% 
derived from traditional twin and family studies27. The discrepancy observed between the 
two methods could be explained by the facts that heritability is underestimated by the ‘chip-
based’ method due to imperfect tagging and it is often overestimated by the traditional twin 
studies due to common environment confounding28. Therefore the actual heritability of 
glycaemic response to metformin could be even higher than what has been estimated from 
GWAS data. In addition, chip-based heritability estimates also suffer underestimation due to 
the incomplete coverage of contribution from rare variants, whereas traditional twin and 
family studies are unbiased in this regard24. Finally, the diversity of the microbiota residing in 
the gut might also contribute to the variable response to metformin. For example, metformin-
associated change in gut microbiome accounts for a considerable proportion of the 
difference in taxonomic composition between patients with T2DM and non-diabetic 
controls29. Examining the diversity of this gut microbiome might, therefore, enable the 
identification of novel targets for the prevention or management of T2DM as the microbiota 
genome is easier to modify with prebiotics or probiotics compared to the host genome30.  
Notably, twin and family studies have been used to estimate the heritability of physiological 
response to antidiabetic agents in participants without T2DM. For example, in a twin-family 
study of 100 healthy twins and 25 siblings, the heritability of GLP-1 stimulated insulin 
secretion during hyperglycaemia to be 53%31. In another family study, the heritability of 
tolbutamide stimulated insulin secretion (Acute Insulin Responsetolbutamide) in 284 healthy 
family members of patients with T2DM was estimated to be 69%32. The results of these twin 
and family studies that include non-diabetic individuals have demonstrated that a large 
component of the variation in physiological measures in response to antidiabetic drugs is 
contributed by genetic variants. However, to what extent such high heritability estimates are 
comparable to that of glycaemic response estimated from population-based studies of 
patients with T2DM is unclear. Two reasons might account for different heritability estimates 
between the two study designs. Firstly, twin and family studies are often performed in 
controlled settings, which have less environmental variance than real world patient 
populations. Consequently, the same genetic effect sizes could lead to higher heritability 
estimates. Secondly, the pharmacodynamics in patients with T2DM might differ from that in 
healthy individuals as the mechanism of glycaemic homeostasis could vary by physiological 
states in which different functional pathways are involved33.  
Most of the robust findings in pharmacogenomic studies to date are related to severe 
ADRs2. The variants associated with these rare ADRs often confer a large risk. For example 
carrying the HLA-B*57:01 allele causes an 80 fold (p=9.0x10-9) increased risk of flucloxacillin 
induced liver injury compared to non-carriers of this allele34. Encouraged by findings like this, 
it has been proposed that many of the drug-response variants should have considerable, 
clinically significant impact on treatment outcome35, 36. This proposal is supported by the 
hypothesis that drug response variants lack the evolutionary constraint that has filtered out 
large disease risk variants via natural selection35. However, two explanations exist as to why 
large impact pharmacogenomics variants are unusual, especially for variants affecting 
treatment efficacy. Firstly, pharmaceutical interventions often achieve clinical impact via 
complex metabolic networks, which rely on redundant pathways and synergistic effects to 
maintain their robustness when confronted with external stimuli37. Partial or complete 
impairment of one node in the network is, therefore, more likely to have marginal impact on 
the treatment efficacy than a complete shutdown on all the relevant pathways. Secondly, the 
established spectrum of large impact ADR variants might also reflect a publication bias, 
which accumulated the so called ‘low hanging fruit’ that have been identified by 
pharmacogenomic studies often using fewer than 1000 cases3, 38. Although the genetic 
architecture of rare ADRs might be akin to those of polygenic diseases in which large impact 
variants dominate3, we anticipate the genetic architecture of treatment efficacy and mild 
ADRs would both encompass a spectrum of rare-to-common variants with moderate effect 
sizes. This notion is in line with the fact that rare variants with moderate impact have been 
successfully identified for common diseases such as T2DM by sequencing and imputation-
based rare variant association studies of over one hundred thousand samples9. Assembling 
large samples would, therefore, enable the identification of more drug response variants by 
future pharmacogenomic studies. 
Pharmacogenomics of T2DM drugs 
Owing to the considerable variability in response to existing drugs to treat diabetes mellitus, 
a large number of pharmacogenetic studies have been published, but only one 
pharmacogenomic GWAS study of metformin treatment efficacy reported39. These studies 
each focused on a single oral agent and have been the subject of many previous reviews 40-
42. No report exists on the pharmacogenetics of drug-drug interaction, despite a large 
number of patients requiring multiple agents to combat diabetes progression and maintain 
glycaemic control. In this section we summarize the replicated findings in studies of 
treatment efficacy and place more emphasis on the investigation of adverse effects (Table 
2). 
Treatment efficacy  
Very few robust pharmacogenetic findings related to treatment efficacy of diabetes mellitus 
drugs have been reported. Previous candidate gene studies largely focused on drug 
transporters or metabolizing enzyme variants that have been implicated in the 
pharmacokinetics of drug exposure41. Variation in metformin pharmacokinetics is mainly the 
result of variants in transporters SLC22A1 (encoding OCT1) and SLC47A1 (encoding 
MATE1)43, 44. However, the most investigated reduced-function OCT1 variants with low 
transporter activity showed no consistent impact on glycaemic control in patients45-48. 
Sulfonylureas are mainly metabolized by Cytochrome P450 2C9  which is encoded by 
CYP2C9. Individuals with the loss-of-function variants in CYP2C9 have higher drug 
exposure, and this in turn does lead to consistent observations of greater glycaemic 
response than those carrying the wild-type alleles49-51.  
Studies of potential pharmacodynamic variants, which might affect how antidiabetic agents 
alter glucose levels, have largely focused on the genes involved in glucose metabolism and 
the risk of developing T2DM. One replicated finding is seen for TCF7L2 and sulfonylurea 
response, where the allele associated with reduced β-cell function and, therefore, increased 
risk of T2DM is also associated with reduced efficacy of sulfonylureas52-54. The K allele of the 
E23K variant in KCNJ11, which encodes the known targets of sulfonylureas, also had 
association with greater glycaemic response in multiple studies55-57. These observations of 
E23K carriers were consistent with the evidence that neonates with monogenic diabetes  
who have causal variants in KCNJ11 could be effectively treated with sulfonylureas18. 
Another replicated finding is the association between PPARG Pro12Ala variant and 
response to Thiazolidinediones (commonly known as TZDs). A few studies each using less 
than 200 participants consistently reported the T2DM risk Pro allele is associated with poor 
glycaemic response 58-60. For the newer agents such as gliptins and SGLT2 inhibitors, 
pharmacogenetic studies of treatment efficacy have been sparse with only one relatively 
large study reporting the association and replication between rs7202877 near CTRB1/2 and 
response to gliptins61. 
The only GWAS of any antidiabetic agent published to date  identified a variant rs11212617 
near the ATM locus being associated with glycaemic response to metformin39. Independent 
replications were later reported in multiple cohorts of different ancestries, strengthening the 
evidence that the variant is the most established drug response variant for antidiabetic 
drug62, 63. Given the moderate impact on glycaemic response to metformin, this variant is not 
a useful biomarker that can substantially increase our ability to accurately predict the 
treatment outcome in individual patients. However, as this variant has no functional link to 
any known metformin mode-of-action, it demonstrates that such a pharmacogenomic 
discovery could reveal novel mechanisms of action of an antidiabetic drug, which might in 
turn identify further pathways to target with new therapeutic agents. The finding that variants 
near ATM are associated with metformin response has prompted further study of the genes 
at this locus in relation to glucose metabolism and metformin response. For example, in a 
small study of patients with ataxia telangiectasia who have recessive loss of function 
mutations in ATM, the investigators identified an impaired glucose tolerance and insulin 
resistance supporting a potential role for ATM in glucose metabolism and metformin 
response64. 
ADRs 
Pharmacogenetic studies have also been performed to help in the understanding of ADRs 
associated with antidiabetic drugs. Key ADRs studied include sulfonylurea-induced 
hypoglycaemia, TZD-associated oedema, hepatotoxicity and heart failure, and metformin 
associated gastrointestinal (GI) disturbance65-69. To date, no studies have been published on 
the pharmacogenomics of the potentially fatal but rare ADRs of metformin-associated lactic 
acidosis70. Thus far, the investigators in all the published pharmacogenetic studies have 
adopted a candidate gene approach. For sulfonylurea-induced hypoglycaemia, a number of 
small studies using no more than 108 patients have been conducted and they consistently 
showed that the loss-of-function CYP2C9 variants, which are associated with increased drug 
exposure66, are also associated with a higher risk of hypoglycaemia65, which is consistent 
with the efficacy studies showing these variants are associated with greater glucose 
reduction than wild-type alleles45. For TZDs, the results have indicated that variants in 
GSTT1 and CYP2C19 were associated with troglitazone-induced hepatotoxicity68, 71; whilst 
variants in NFATC2 are associated with the rate of rosiglitazone-induced oedema67. 
Although some safety concerns have been raised against the newer agents, such as genital 
and urinary tract infections associated with SGLT2 inhibitors and the pancreatitis and liver 
dysfunction associated with gliptins70, to our knowledge, no pharmacogenetic reports on 
these ADRs exist. 
Metformin causes gastrointestinal disturbance in as many as 20-40% of patients with 5-10% 
of patients not being able to tolerate this drug70. The biological mechanism for 
gastrointestinal intolerance to metformin remains poorly understood. Based on the 
hypothesis that individuals who are intolerant of metformin are exposed to higher 
concentrations of the drug in the gastrointestinal tract, investigators have explored variants 
in transporter genes such as OCT172. In a large study of 2,166 patients, both reduced-
function variants in OCT1 and co-medication of certain OCT1 inhibitors (that is, verapamil, 
proton pump inhibitors, citalopram, codeine and doxazosin) significantly increased the risk of 
metformin induced gastrointestinal side effect69. The combination of carrying the genetic 
variants and taking co-medications could result in a four-fold (p<0.001) increased risk of 
gastrointestinal side effect69. Therefore this large impact on metformin induced 
gastrointestinal side effects by these OCT1 variants have the potential to be translated into 
clinical practice by prescreening the patients on OCT1 genotype and co-medication of OCT1 
inhibitors. Moreover, this study  highlighted two key factors for successful 
pharmacogenomics of antidiabetic drugs: large sample sizes are required for adequate 
statistical power; and the need to consider co-prescribed medication that potentially interacts 
with these agents. This result has since been replicated in an independent study which 
showed the same genetic variants were associated with increased risk (OR=2.3; p=0.02) of 
less severe metformin intolerance73. 
Genetics and drug target validation  
A major challenge in the modern pharmaceutical industry is that fewer than 15% of drugs 
entering the development pipeline make it to market74, a vastly expensive, inefficient and 
wasteful process. Toxicity and lack of efficacy both contribute to the high failure rate of new 
drugs development, which reflects the ineffectiveness of conventional target validation 
methods used in preclinical studies. Moreover, the model systems used in the preclinical 
studies often fail to represent the real biological system working in humans.  
Genetic variants that arise as a result of historical mutation and recombination events can be 
viewed as naturally occurring experiments that perturb human gene function. These naturally 
occurring mutations are an opportunity to see the impact of perturbing a gene (for example, 
by a potential novel drug) on disease risk and off-target effects without the need to develop 
and trial the drug. For example, in a large survey of 61,104 drugs across the various stages 
of development, those drug candidates that targeted proteins encoded by genes with robust 
human genetic evidence (GWAS evidence or link to Mendelian diseases in OMIM) are twice 
as likely to be therapeutically valid75.  
To address the question of how to harness the human genetic evidence to guide target 
validation in drug development, the ‘therapeutic hypothesis’ has been proposed76. Central to 
this approach is the concept of a genetic evidence based ‘dose-response’ curve. An 
example of translating such a hypothesis into a new drug is the development of the PCSK9 
inhibitors to reduce levels of LDL cholesterol77. Rare ‘gain-of-function’ variants in PSCK9 led 
to high levels of LDL cholesterol and increased the incidence of coronary heart disease 
risk78. Conversely, rare ‘loss-of-function’ variants resulted in lower LDL cholesterol levels and 
a reduced risk of coronary heart disease79. GWAS also identified common variants in other 
genes such as SORT1 and LDLR with mild impact on LDL cholesterol levels and risk of 
coronary heart disease80, 81. These experiments (which are essentially designed by nature) 
have demonstrated that reducing levels of LDL cholesterol and the risk of coronary heart 
disease is possible by inhibiting the function of PCSK9 without any observable adverse 
effects77. With further support by other mechanistic evidence derived from model systems, a 
new generation of LDL cholesterol lowering PCSK9 inhibitors have been developed, tested 
and licensed for use82. 
Dozens of common and rare variants have been convincingly associated with glycaemic 
control and the risk of developing T2DM10. Representatives from both academia and 
pharmaceutical companies have now formed the Accelerating Medicines Partnership to 
enhance the translation of human genomic research outputs into the development of new 
drugs (https://www.nih.gov/research-training/accelerating-medicines-partnership-amp)83. As 
one of the three prioritized area, the Accelerating Medicines Partnership aims to establish an 
open-access portal for T2DM genetics research (http://www.type2diabetesgenetics.org), 
which will pool genomic and phenotyping data to facilitate novel data mining efforts83. One 
target of potential interest raised by the Accelerating Medicines Partnership is the zinc-
transporter-encoding SLC30A8. The use of GWAS has established robust evidence that the 
common coding variant Arg325Trp is associated with the risk of T2DM84. The results of 
mechanistic studies in humans and mice have both indicated that the reduced zinc 
transporter activity allele is associated with an increased risk of T2DM85, 86However, in a 
sequencing based study of ~150,000 individuals, rare protein-truncating variants In 
SLC30A8 protected the carriers from developing T2DM9. This conflicting genetic evidence 
does not provide a consistent dose-response curve based on the functional characterization 
of the variants87. Further mechanistic studies, especially those involving intensive 
phenotyping of individuals carrying rare extreme functional SLC30A8 variants will be useful 
to validate whether inhibiting or enhancing the zinc transporter 8 function could be the 
therapeutic option for treating T2DM. The example provided by SLC30A8 demonstrates that 
human genetic evidence is not always sufficient to validate a gene/protein as a drug target, 
especially in situations when uncertainty surrounds the exact mechanism of how target 
genes alter a phenotype of interest. 
The discovery of sodium glucose transporter 2 (SGLT2) inhibitors to treat T2DM is another 
example of how genetic evidence can be used in assisting drug development (Figure 2). 
Early evidence indicated that phlorizin, a natural inhibitor of SGLT2 and isolated from the 
bark of apple trees, restored euglycaemia and insulin sensitivity in animal models of T2DM88. 
After the cloning of SLC5A2 which encodes SGLT2, functional variants in SGLT2 have been 
linked to familial renal glycosuria (http://www.omim.org/entry/233100)89. Patients with familial 
renal glycosuria, who carry a spectrum of >50 mild heterozygote to severe homozygote 
SGLT2 loss-of-function variants, have different levels of glycosuria but apparently normal 
renal functions, normal glucose concentrations and general health90. Here the genetic 
evidence not only validated the therapeutic potential of inhibiting SGLT2 but also provided 
critical evidence that selective inhibitors targeting the protein would result in no long-term 
ADRs. Consequently, several selective SGLT2 inhibitors have been successfully developed 
and licensed to treat T2DM14. Aside from their glucose lowering effect, these SGLT2 
inhibitors have an average impact of 1.63kg (p<0.001) weight reduction benefit16, 91, which is 
increasingly being considered as an important component in the management of T2DM92.  
Pharmacogenomics and drug discovery 
Conventional pharmacogenetics, which is based on candidate genes has been used in all 
stages of the drug development pipeline, from target identification, to clinical trials and 
postmarket analysis of ADRs35. As pharmacogenetics moves to pharmacogenomics, this 
genome-wide hypothesis free approach could also have more applications in drug discovery 
and development20. 
The proposed ’therapeutic hypothesis’ is based on the principle that human genetics is an 
experiment of nature, which shows what phenotypic outcomes the natural perturbations of 
gene functions can lead to in a human population76. Clearly human genetics has the 
advantage that the experimental system is in living humans as opposed to the cell or animal 
model systems used in preclinical studies. However, the ideal system for validating a 
therapeutic hypothesis would be a genetic study carried out in the exact context the new 
drug is developed for. Genetic evidence of disease risk could be useful in validating the 
targets for a preventive drug but less informative to predict the therapeutic potential for 
disease management. For example, let us consider using human genetic evidence to 
validate candidate drug targets to improve glycaemic control in patients with T2DM. The 
most available candidates would be those genes with established variants associated with 
the risk of developing T2DM or poor glycaemic control in the general population. However, it 
has been suggested that the mechanism regulating glycaemia can vary between different 
physiological states33. The variants affecting glycaemia in normal individuals and those 
associated with T2DM risk only partially overlap33, suggesting perturbations of glycaemia are 
not always linked to the risk of T2DM. Similarly, the variants conferring risk to T2DM have 
little impact on the rate of disease progression93, which suggests that the mechanism 
controlling glycaemia when T2DM has developed might be different from those involved in 
its development. Consequently, targeting the genes involved in regulation of glycaemia in 
healthy individuals or the risk of T2DM might not have the desired glycaemic impact on the 
management of T2DM, especially if their biological functions have been altered by the onset 
of the disease. In the context of disease management, pharmacogenomic studies of existing 
antidiabetic drugs can identify genes involved in glycaemic control in patients with T2DM. 
Robust pharmacogenomic findings would, therefore, provide physiological state specific 
information for drug target validation in addition to other evidence of normal glycaemic 
control and risk of T2DM derived from human genetic studies.  
Table 1 outlines the differences between pharmacogenomic studies of drugs to treat T2DM 
and genomics of other diabetes mellitus-related traits. Compared to the wealth of findings 
from other areas of human genetics, to date pharmacogenomics has yielded less robust 
results, in part owing to the challenge to assemble tens of thousands of samples that could 
provide adequate statistical power to detect variants with moderate effect. However, we 
anticipate future drug discovery and drug development to benefit more from the 
pharmacogenomic findings derived from larger samples that are increasingly available from 
biobanks linked to electronic health record data (e.g. the UKBiobank). Notably, longitudinal 
data from clinical trials or health record linkage do enable the study of outcomes other than 
simple measures of glycaemia. For example, given a sufficient sample size, using 
pharmacogenomics to assess cardiovascular endpoints of antidiabetic drugs might be 
possible. In addition, large samples would also enable pharmacogenomics to joint analyse 
multiple outcomes (for example both glycaemic benefit and weight benefit of metformin), 
which would help to identify variants associated with pleiotropic effects of antidiabetic drugs.  
Avoiding ADRs or off-target effects is also an important consideration in drug development. 
The very existence of ADRs is an illustration of our incomplete understanding of the complex 
interactions between our biological system and any designed interventions94. The increased 
availability of genome-wide screening tools will enable the identification of more ADR 
variants at an early stage of drug development, which has a number of clear advantages. 
For example, if the ADR variants were identified before phase 3 clinical trials, recruitment by 
genotype trials could be performed to evaluate the efficacy and risk in stratified patient 
subgroups35. When a drug is approved for marketing, understanding the genetic basis of 
severe ADR could also help the continuous development of the drug by prescreening the 
genotype ahead of treatment95. 
A system biology view of drug response 
One of the biggest challenges facing contemporary biological research is to understand the 
complex biological networks that function in a living system96. This complexity can be seen in 
T2DM, where the genes harbouring the established aetiological variants have an excess of 
interactions within a high-confidence interaction network97. The variants in this network affect 
the protein function, stability of protein or transcript, and expression of individual genes, 
which collectively perturb or rewire the network structure to alter the risk of T2DM98, 99. 
Interestingly, when considering a network of disease genes and genes encoding known drug 
targets, the distance between genes reported in GWAS and known drug targets are shorter 
than that between random gene-drug targets pairs100. This is predominantly driven by a 
three-fold enrichment of drug target genes among the first neighbours of the GWAS reported 
genes. More evidence of direct overlap between the drug target genes and disease risk 
genes was also presented in a gene set enrichment analysis101. In this study a set of 102 
target genes for existing diabetes mellitus drugs (e.g. insulin, metformin and TZDs), as 
curated from the literature, showed significant enrichment of genetic association with T2DM 
susceptibility101. Such findings indicate that potential drug targets are enriched in a disease 
network, but might only be identified when considering the network as a whole, rather than 
individual disease genes.  
When modelling a drug intervention in a functional network, it is important to consider how 
the drug alters the functional network at the levels of cell, tissue and disease state, which will 
ultimately determine the beneficial and harmful effects of the drug. So far our knowledge of 
biological networks has been largely limited to the generic, static models lacking such 
contextual information102. Research in system biology is beginning to offer more 
comprehensive cell lineage and tissue specific networks103-105, which will enable the 
modelling of drug intervention in more specific contexts such as the cell type, tissue and the 
physiological state. Such analyses will provide insights into how drugs can achieve the 
desired therapeutic effect in target tissue or known site of action, but importantly highlight the 
potential undesirable off-target effects in other contexts. Moreover, adopting a system-wide 
approach might change the focus of drug development for complex diseases such as T2DM 
from targeting an individual protein or gene to system-wide attacks on multiple dynamic 
targets106.  
Conclusions 
The availability of affordable high-throughput genomic technologies has expanded our 
knowledge about the multifactorial aetiology of T2DM. Studies adopting such genome-wide 
approaches to investigate the response of existing antidiabetic drugs have been limited, but 
have the potential to improve our understanding of the biological mechanisms underlying 
treatment efficacy and side effects. With the major investments in precision medicine in the 
US107, the 100,000 genomes project in the UK108, and the EU funded stratified medicine in 
diabetes mellitus initiative IMI-DIRECT109 (Innovative Medicines Initiative: DIabetes 
REsearCh on patient straTification), more findings from adequately powered 
pharmacogenomic studies are expected to complement other human genetic discoveries to 
facilitate more efficient antidiabetic drug discovery programs. 
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 Key points 
• The list of known variants affecting type 2 diabetes mellitus (T2DM) risk confirms that 
this disease has a multifactorial aetiology 
• The concept of precision medicine has been exemplified in pharmacogenetic studies 
of monogenic diabetes  
• The genetic architecture of mild adverse drug reactions and treatment efficacy for 
antidiabetic agents probably resembles that of T2DM and other complex traits 
• Existing pharmacogenetic evidence of T2DM is limited; future pharmacogenomics 
studies utilizing large samples will help identify variants that reveal novel mechanism 
of drug action 
• Genetic evidence-based ‘dose-response’ curves have been used in validating 
candidate drug targets 
• Pharmacogenomic studies adopting a system biology approach are expected to 
provide context specific evidence for future T2DM drug development  
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Figure 1 | Target organs and action mechanism of antidiabetic drugs. The 
mechanism for metformin action remains uncertain: metformin might target the liver 
to reduce gluconeogenesis and skeletal muscles to enhance peripheral glucose 
utilization110 with a possible role in the gut to increase levels of GLP-1111. 
Sulfonylureas and meglitinides increase insulin secretion in the pancreas112, 113. 
Thiazolidinediones (TZDs) act as insulin sensitizers in the skeletal muscle, adipose 
tissue and the liver114. GLP-1 agonists target the pancreas to increase insulin 
secretion and reduce glucagon production, as well as act in the gut to reduce gastric 
emptying115. DPP-4 inhibitors increase the level of endogenous incretin levels by 
blocking the action of a catalytic enzyme DPP-4115. SGLT-2 inhibitors reduce renal 
glucose reabsorption116. Abbreviations: DDP4, dipeptidyl peptidase 4, GLP1RA, 
glucagon like peptide 1 receptor agonist, SGLT2I, sodium glucose transporter 2 
inhibitor
 
 Figure 2 | Dose-response curve for the therapeutic hypothesis of selective SGLT2 
inhibitors. The Y axis represent the range of glucose level, in which the high range 
represents the hyperglycaemic state seen in T2DM as compared to the normal range seen 
in healthy individuals or those patients with familial renal glycosuria. The X axis represents a 
spectrum of naturally occurring SGLT2 loss-of-function variants observed in patients with 
familial renal glycosuria. The variants were ordered from the mild heterozygotes to the 
severe homozygotes as defined by the resulting severity of glycosuria. For on-target adverse 
reactions, the benign glucosuria and apparently normal health seen in these patients also 
supports the safety profile of selectively inhibiting SGLT2 function in a wide dose window. 
Abbreviation: SGLT2, sodium glucose transporter 2. 
 
  
 Table 1 | Pharmacogenomic studies of antidiabetic drugs and genomic studies of other diabetes 
mellitus-related traits 
 Pharmacogenomics of antidiabetic 
drugs  
Genomic studies of other diabetes 
mellitus-related traits  
Sample sizes Currently <10,000 individuals Currently >100,000 individuals 
Number of 
established 
variants 
Only a few >120 for T2DM risk 
>83 for other diabetes mellitus-related 
traits 
Data type Longitudinal Cross sectional 
Outcomes Physiological response e.g. 
insulin secretion 
Treatment efficacy: glucose 
reduction 
Hard endpoints: cardiovascular 
risk 
Other outcomes: weight 
reduction 
Onset of type 2 diabetes 
Hyperglycaemia: fasting glucose level, 
HbA1c levels 
Insulin resistance: HOMA-IR 
Insulin secretion: fasting insulin level, 
fasting C-peptide, HOMA-B 
 
Table 1. This table highlights that the published GWAS of response to antidiabetic agents used 
considerably smaller sample sizes, and therefore established less variants, than those GWAS of other 
diabetes mellitus-related traits.  Given that more longitudinal data in large samples are increasingly 
available through large bioresources such as the UkBiobank, pharmacogenomic studies are expected 
to provide more insights into the genetic basis of various drug response phenotypes.  
Table 2. Replicated pharmacogenetic findings of antidiabetic agents 
 
NA means no evidence has been published on the drug-outcome pair. 
 
  
Agent Treatment Efficacy ADRs 
Metformin HbA1c reduction: ATM39, 62 
 
Gastrointestinal side effects: 
OCT169, 73 
Lactic Acidosis: (NA) 
Sulfonylureas HbA1c reduction: TCF7L252-54, 
KCNJ1155-57 and CYP2C949, 51 
Maintenance dose: CYP2C950  
Hypoglycaemia: CYP2C965 
Thiazolidinedione 
(TZDs) 
HbA1c/Glucose reduction: 
PPARG58-60 
troglitazone-induced 
hepatotoxicity: GSTT168 and 
CYP2C1971 
 
Gliptins  
(DPP4i) 
HbA1c reduction (insulin 
response): CTRB1/261 
pancreatitis and liver 
dysfunction: (NA) 
SGLT2i NA genital and urinary tract 
infections: (NA) 
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